About Us
Copyright(c) 2011 Eisai China lnc.All Rights Reserved.
»¦ICP±¸11005394ºÅ-1
»¦¹«Íø°²±¸31010602001439ºÅ
Customer Service Hotline
021-62881220
LINKS
? Record information of Representative
? ÒÑÉÏÊÐÌæÆÕÈðͪ½ºÄÒ¸õÏÞÁ¿¼ìÑ鱨¸æ¹«Ê¾ËµÃ÷
The News
14
2024/08
2024/08
Eisai and Biogen announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (A¦Â) monoclonal antibody ¡°LEQEMBI?¡± (lecanemab) for the treatment of Alzheimer¡¯s disease (AD).
06
2024/08
2024/08
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ¡°Eisai¡±) reconfirmed today that the regulatory
status for anti-amyloid beta (A¦Â) protofibril antibody LEQEMBI? (generic name: lecanemab) subcutaneous
(SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows.
27
2024/05
2024/05
Eisai and Biogen announced today that the Ministry of Food and Drug Safety
(MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (A¦Â)
monoclonal antibody ¡°LEQEMBI?¡± (lecanemab) for treatment in adult patients with mild cognitive
impairment due to Alzheimer¡¯s disease (AD) or mild AD (early AD).
15
2024/05
2024/05
Eisai and Biogen announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI?) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA.
Eisai¡¯s affiliates in China are wholly-owned by Eisai Co., Ltd. (Eisai), a Japanese multinational pharmaceutical company with strong R&D capabilities, as global headquarter in Tokyo and headquarter of China in Shanghai.
Eisai has grown smoothly since entering the Chinese market in the early 1990s and the total …